Adoptive T-cell therapy as a therapeutic option for chronic hepatitis B

Journal of Viral Hepatitis

Volumn 14, Issue SUPPL. 1, 2007, Pages 45-50

  Bohne, F ^b   Protzer, U ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Adoptive T cell transfer; Chimeric TCR; HBV; T cell receptor

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; GAMMA INTERFERON; HEPATITIS B VACCINE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; NUCLEOSIDE DERIVATIVE; NUCLEOTIDE DERIVATIVE; RECOMBINANT RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; CELL THERAPY; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CONFERENCE PAPER; DEPRESSION; DISEASE SEVERITY; ERADICATION THERAPY; FEVER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MYALGIA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; THROMBOCYTOPENIA; TREATMENT PLANNING; VACCINATION;

HEPATITIS B, CHRONIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES;

EID: 35448951348     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00913.x     Document Type: Conference Paper

References (49)

1. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004 350 (11 1118 1129.
2. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005 5 (3 215 229.
3. Bertoletti A, Ferrari C, Fiaccadori F et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A 1991 88 (23 10445 10449.
4. Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995 181 (3 1047 1058.
5. Penna A, Chisari FV, Bertoletti A et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991 174 (6 1565 1570.
6. Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996 98 (5 1185 1194.
7. Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer-Semin Immunopathol 1995 17 (2-3 261 281.
8. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 45 (4 529 538.
9. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982 29 (2 403 415.
10. Ganem D, Schneider R. Hepadnaviridae the viruses and their replication. In: B. Fields, D.M. Knipe, P.M. Howley ed. Field′s Virology 4th edn. Philadelphia, PA: Lipincott-Raven, 2001.
11. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000 64 (1 51 68.
12. Lok AS. Navigating the maze of hepatitis B treatments. Gastroenterology 2007 132 (4 1586 1594.
13. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 (2 507 539.
14. Conberg M, Protzer U, Dollinger M, Petersen J et al. Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus (HBV) Infection: Upgrade of the German Guideline. Z. Gastroenterologie 2007 45: 525 574.
15. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 (1 65 73.
16. Wu GY, Chen HS. Novel approaches towards conquering hepatitis B virus infection. World J Gastroenterol 2007 13 (6 830 836.
17. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007 45 (4 1056 1075.
18. Zhang YY, Zhang BH, Theele D, Litwin S, Toll E, Summers J. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci U S A 2003 100 (21 12372 12377.
19. Wieland SF, Spangenberg HC, Thimme R, Purcell RH, Chisari FV. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci U S A 2004 101 (7 2129 2134.
20. Addison WR, Walters KA, Wong WW et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002 76 (12 6356 6363.
21. Zhu Y, Yamamoto T, Cullen J et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001 75 (1 311 322.
22. Loomba R, Liang TJ. Novel approaches to new therapies for hepatitis B virus infection. Antivir Ther 2006 11 (1 1 15.
23. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007 117 (5 1204 1212.
24. Hui CK, Lie A, Au WY et al. A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation. Blood 2005 106 (2 464 469.
25. Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995 333 (16 1038 1044.
26. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995 345 (8941 9 13.
27. Comoli P, Pedrazzoli P, Maccario R et al. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 2005 23 (35 8942 8949.
28. Savoldo B, Huls MH, Liu Z et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002 100 (12 4059 4066.
29. Sun J, Gao Y, Chen HS et al. Transfusion of multi-factors activated immune cells as a novel treatment for patients with chronic hepatitis B. J Clin Virol 2006 35 (1 26 32.
30. Leen AM, Myers GD, Sili U et al. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 2006 12 (10 1160 1166.
31. Hess C, Altfeld M, Thomas SY et al. HIV-1 specific CD8+ T cells with an effector phenotype and control of viral replication. Lancet 2004 363 (9412 863 866.
32. Schmitz JE, Kuroda MJ, Santra S et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999 283 (5403 857 860.
33. Walker RE, Bechtel CM, Natarajan V et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000 96 (2 467 474.
34. Appay V, Nixon DF, Donahoe SM et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000 192 (1 63 75.
35. Engels B, Uckert W. Redirecting T lymphocyte specificity by T cell receptor gene transfer - a new era for immunotherapy. Mol Aspects Med 2007 28 (1 115 142.
36. Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J Antimicrob Chemother 2000 45 (Suppl. T3 35 43.
37. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006 6 (5 383 393.
38. Uherek C, Groner B, Wels W. Chimeric antigen receptors for the retargeting of cytotoxic effector cells. J Hematother Stem Cell Res 2001 10 (4 523 534.
39. Chamoto K, Tsuji T, Funamoto H et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 2004 64 (1 386 390.
40. Cooper LJ, Kalos M, Lewinsohn DA, Riddell SR, Greenberg PD. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol 2000 74 (17 8207 8212.
41. Ueno T, Fujiwara M, Tomiyama H, Onodera M, Takiguchi M. Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes. Eur J Immunol 2004 34 (12 3379 3388.
42. Abken H, Hombach A, Heuser C. Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. Curr Pharm Des 2003 9 (24 1992 2001.
43. Masiero S, Del Vecchio C, Gavioli R et al. T-cell engineering by a chimeric T-cell receptor with antibody-type specificity for the HIV-1 gp120. Gene Ther 2005 12 (4 299 310.
44. Roberts MR, Qin L, Zhang D et al. Targeting of human immunodeficiency virus-infected cells by CD8+ T lymphocytes armed with universal T-cell receptors. Blood 1994 84 (9 2878 2889.
45. Yang OO, Tran AC, Kalams SA, Johnson RP, Roberts MR, Walker BD. Lysis of HIV-1-infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci U S A 1997 94 (21 11478 11483.
46. Bohne F, Chmielewski M, Ebert G. T cells Redirected Against Hepatitis B Virus Surface Proteins Eliminate Infected Hepatocytes. Gastroenterology, in press.
47. Basta S, Stoessel R, Basler M, van den Broek M, Groettrup M. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. J Immunol 2005 175 (2 796 805.
48. Sommermeyer D, Neudorfer J, Weinhold M et al. Designer T cells by T cell receptor replacement. Eur J Immunol 2006 36 (11 3052 3059.
49. Germain RN, Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 1999 17: 467 522.